

Provisional 2021 EphMRA ATC Developments

The following new class structures were voted on by EphMRA/PBIRG in May/June 2020 and agreed in principle. These structures will now be used in the next part of the development process which is the detailed refinement of the rules.

Please note that these new class structures are provisional at this time. The 2021 codes, descriptions and Guideline text will be finalised and published by the Committee at the end of 2020. The new structures then come into effect from the beginning of 2021.

Vaccines

Vaccines against the coronavirus group, including COVID-19.

J7E6 (new)	Coronavirus vaccines
	Includes vaccines against COVID-19.

Antineoplastics, protein kinase inhibitors

Inhibitors of Bruton's tyrosine kinase (BTK).

L1H6 (new)	Protein kinase inhibitor antineoplastics, BTK
	Includes products containing acalabrutinib, ibrutinib, zanubrutinib, etc.

Cystic fibrosis

Cystic fibrosis transmembrane regulator (CFTR) modulators.

R7B (new)	CYSTIC FIBROSIS PRODUCTS
R7B1 (new)	Cystic fibrosis transmembrane regulator (CFTR) modulators
	Includes products containing eg elexacaftor, ivacaftor, lumacaftor, tezacaftor, etc for cystic fibrosis.

Idiopathic pulmonary fibrosis

Products for idiopathic pulmonary fibrosis.

R7D (new)	IDIOPATHIC PULMONARY FIBROSIS PRODUCTS
	Includes products containing eg, pirfenidone, nintedanib, etc for idiopathic pulmonary fibrosis.